n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with 2,3-dinor-6-ketoprostaglandin f1alpha in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adderley, SR; Cunningham, AJ; Dowd, NP; Fitzgerald, DJ; Scully, M | 1 |
1 other study(ies) available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and 2,3-dinor-6-ketoprostaglandin f1alpha
| Article | Year |
|---|---|
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonic Acid; Aspirin; Biomarkers; Cardiomyopathies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Doxorubicin; Enzyme Induction; Epoprostenol; Heart; Iloprost; Isoenzymes; L-Lactate Dehydrogenase; Male; Membrane Proteins; Myocardium; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Thromboxane B2; Transcription Factors; Troponin T | 2001 |